Shanghai Cell Therapy Group

Recent Finacing

Series D I

Recent Raise

$76.7M

Shanghai Cell Therapy Group develops non‑viral CD19 CAR‑T and other cellular immunotherapies, operates large‑scale CAR‑T manufacturing, clinical hospitals, and cell banking/cryopreservation services compliant with CFDA, USFDA and JCI.

Founded 2013

Shanghai, China

501-1K

Private

shcell.com

Highlights

Focus Areas

Biotechnology

Therapeutics

Recent Investors

N

A

盛

Financials

$210.8M

Total Raised

2

Funding rounds

9

Investors

Team

Upgrade to view the team

See the team members at Shanghai Cell Therapy Group.